HER-2, notch, and breast cancer stem cells

Targeting an axis of evil

Hasan Korkaya, Max S. Wicha

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Increasing evidence indicates that tumor-initiating (cancer stem) cells may contribute to treatment resistance and relapse,suggesting that improved clinical outcome will require effective targeting of this cell population. Recent studies suggest that the remarkable clinical efficacy of trastuzumab may relate to its ability to target cancer stem cell populations.

Original languageEnglish (US)
Pages (from-to)1845-1847
Number of pages3
JournalClinical Cancer Research
Volume15
Issue number6
DOIs
StatePublished - Mar 15 2009

Fingerprint

Neoplastic Stem Cells
Breast Neoplasms
Population
Recurrence
Neoplasms
Trastuzumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

HER-2, notch, and breast cancer stem cells : Targeting an axis of evil. / Korkaya, Hasan; Wicha, Max S.

In: Clinical Cancer Research, Vol. 15, No. 6, 15.03.2009, p. 1845-1847.

Research output: Contribution to journalArticle

@article{2db052dd8020464db6c107bbf52236ac,
title = "HER-2, notch, and breast cancer stem cells: Targeting an axis of evil",
abstract = "Increasing evidence indicates that tumor-initiating (cancer stem) cells may contribute to treatment resistance and relapse,suggesting that improved clinical outcome will require effective targeting of this cell population. Recent studies suggest that the remarkable clinical efficacy of trastuzumab may relate to its ability to target cancer stem cell populations.",
author = "Hasan Korkaya and Wicha, {Max S.}",
year = "2009",
month = "3",
day = "15",
doi = "10.1158/1078-0432.CCR-08-3087",
language = "English (US)",
volume = "15",
pages = "1845--1847",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - HER-2, notch, and breast cancer stem cells

T2 - Targeting an axis of evil

AU - Korkaya, Hasan

AU - Wicha, Max S.

PY - 2009/3/15

Y1 - 2009/3/15

N2 - Increasing evidence indicates that tumor-initiating (cancer stem) cells may contribute to treatment resistance and relapse,suggesting that improved clinical outcome will require effective targeting of this cell population. Recent studies suggest that the remarkable clinical efficacy of trastuzumab may relate to its ability to target cancer stem cell populations.

AB - Increasing evidence indicates that tumor-initiating (cancer stem) cells may contribute to treatment resistance and relapse,suggesting that improved clinical outcome will require effective targeting of this cell population. Recent studies suggest that the remarkable clinical efficacy of trastuzumab may relate to its ability to target cancer stem cell populations.

UR - http://www.scopus.com/inward/record.url?scp=63449116164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63449116164&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-3087

DO - 10.1158/1078-0432.CCR-08-3087

M3 - Article

VL - 15

SP - 1845

EP - 1847

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -